New Pet Allergy Treatments May Be on the Horizon
Bayer and NeuroCycle Therapeutics have signed a global license agreement with plans to bring to market new treatments for allergies in dogs and cats.
Increasing numbers of pet owners are demanding more effective and convenient treatment options for their furry family members. To help meet this demand,
Bayer Animal Health GmbH and NeuroCycle Therapeutics, Inc. (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals.
As part of the agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT, a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule drugs that target the central nervous system. Additional terms of the agreement were not disclosed.
- Top 5 Ailments for Dogs and Cats
- Top Age-Related Issues in Pets
“At Bayer, we are committed to helping pet owners improve the health and well-being of their animals,” said Dr. Sabine Bongaerts, Bayer’s head of development. “We know that allergies are among the most important health and well-being concerns for pet owners and veterinarians. The license agreement with NCT is a strong signal of our commitment to our customers around the world to address these concerns.”
Douglas Hutchens, DVM, PhD, Bayer’s head of drug discovery, external innovation & chief veterinary officer, added: “[This] agreement underlines our strategy to combine the know-how from creative start-up companies like NCT with opportunities derived from Bayer’s research. It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector. Now, we will focus on evolving these options from research and development to market maturity.”
NeuroCycle Therapeutics CEO Jed Hubbs, PhD, noted: “Our goal is to maximize the humanitarian impact of our innovative technologies. This license agreement with Bayer Animal Health aligns with this goal by allowing our technology to be applied beyond our core focus on human health.”